<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03372629</url>
  </required_header>
  <id_info>
    <org_study_id>ID-085-101</org_study_id>
    <secondary_id>2017-004124-30</secondary_id>
    <nct_id>NCT03372629</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate if ID-085 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects</brief_title>
  <official_title>A Two-part Single-center, Phase 1 Study to Assess the Tolerability, Safety, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of Ascending Single and Multiple Doses of ID-085 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the tolerability, safety, and pharmacokinetic of
      single- and multiple-ascending doses of ID-085 in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed in two parts, A and B.

      Part A: single-center, double-blind, randomized, placebo-controlled, single ascending dose.

      Part B: single-center, double-blind, randomized, placebo-controlled, multiple ascending dose.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 12, 2018</start_date>
  <completion_date type="Anticipated">September 28, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 28, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in PQ/PR interval (ms)</measure>
    <time_frame>up to 48 hours post-dose (Part A); up to Day 10 (Part B)</time_frame>
    <description>ECG variables are to be recorded using a standard 12-lead ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in QRS interval (ms)</measure>
    <time_frame>up to 48 hours post-dose (Part A); up to Day 10 (Part B)</time_frame>
    <description>ECG variables are to be recorded using a standard 12-lead ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in QT corrected for Bazett's formula (QTcB) interval (ms)</measure>
    <time_frame>up to 48 hours post-dose (Part A); up to Day 10 (Part B)</time_frame>
    <description>ECG variables are to be recorded using a standard 12-lead ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in RR interval (ms)</measure>
    <time_frame>up to 48 hours post-dose (Part A); up to Day 10 (Part B)</time_frame>
    <description>ECG variables are to be recorded using a standard 12-lead ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in heart rate (bpm)</measure>
    <time_frame>up to 48 hours post-dose (Part A); up to Day 10 (Part B)</time_frame>
    <description>ECG variables are to be recorded using a standard 12-lead ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in supine systolic blood pressure</measure>
    <time_frame>up to 48 hours post-dose (Part A); up to Day 10 (Part B)</time_frame>
    <description>mm Hg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in supine diastolic blood pressure</measure>
    <time_frame>up to 48 hours post-dose (Part A); up to Day 10 (Part B)</time_frame>
    <description>mm Hg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in supine pulse rate</measure>
    <time_frame>up to 48 hours post-dose (Part A); up to Day 10 (Part B)</time_frame>
    <description>bpm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in body weight</measure>
    <time_frame>up to 48 hours post-dose (Part A); up to Day 10 (Part B)</time_frame>
    <description>kg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with treatment-emergent AEs and SAEs for each treatment period</measure>
    <time_frame>up to 48 hours post-dose (Part A); up to Day 10 (Part B)</time_frame>
    <description>Treatment-emergent AEs and treatment-emergent serious AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>up to Day 3 (Part A), up to Day 10 (Part B)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (tmax)</measure>
    <time_frame>up to Day 3 (Part A), up to Day 10 (Part B)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life [t(1/2)]</measure>
    <time_frame>up to Day 3 (Part A), up to Day 10 (Part B)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from zero to time t of the last measured concentration above the limit of quantification (AUC0-t)</measure>
    <time_frame>up to Day 3 (Part A), up to Day 10 (Part B)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>ID-085, single ascending dose (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ID-085 administered at different single dose levels in a sequential manner, and in a maximum of 6 dose levels starting from 10 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, single ascending dose (Part A)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo administered as single ascending doses in parallel to ID-085</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ID-085 multiple ascending dose (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ID-085 administered in a twice daily (b.i.d.) dosing regimen at multiple dose levels. The starting dose will be either 10 or 30 mg and will be selected on the basis of the safety and pharmacokinetic results of the part A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, multiple ascending dose (Part B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo administered as single ascending doses in parallel to ID-085</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ID-085</intervention_name>
    <description>Hard gelatin capsules for oral administration formulated in strengths of 10 mg, 100 mg, and 200 mg</description>
    <arm_group_label>ID-085, single ascending dose (Part A)</arm_group_label>
    <arm_group_label>ID-085 multiple ascending dose (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo capsules matching ID-085 capsules</description>
    <arm_group_label>Placebo, single ascending dose (Part A)</arm_group_label>
    <arm_group_label>Placebo, multiple ascending dose (Part B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent in the local language prior to any study-mandated procedure.

          -  Healthy male subjects for Part A, healthy male and female subjects for Part B aged
             between 18 and 55 years (inclusive) at screening.

          -  No clinically significant findings on physical examination at screening.

          -  Body mass index (BMI) of 18.0 to 30.0 kg/m2 (inclusive) at screening.

        Exclusion Criteria:

          -  History or clinical evidence of any disease and/or existence of any surgical or
             medical condition that might interfere with the absorption, distribution, metabolism
             or excretion of the study treatment (appendectomy and herniotomy allowed,
             cholecystectomy not allowed).

          -  Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal
             reactions.

          -  Pregnant or lactating women.

          -  Known allergic reactions or hypersensitivity to the study treatment or drugs of the
             same class, or any of the excipients.

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martine Géhin, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CTD Clinical Trial Disclosure desk</last_name>
    <phone>+41 58 844 00 00</phone>
    <email>clinical-trials-disclosure@idorsia.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Principal Investigator</last_name>
    <phone>0800 591 570</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Covance Clinical Research Unit - Clinical Pharmacology Services</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2017</study_first_submitted>
  <study_first_submitted_qc>December 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2017</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

